

# Xenobiotic Metabolism

## Overview of Key Concepts & Components

**Xenobiotics**  
Drugs, Environmental Toxins

Modulation by:

Induction

Inhibition

Disease

Genetic Variability

### Phase 1

Addition or unmasking of a functional polar group. Typically results in a relatively small increase in hydrophilicity. May cause metabolic activation

Cytochromes P450  
Flavin monooxygenases  
Epoxide Hydrolase  
Hydrolases  
Carboxyl Esterases  
Alcohol Dehydrogenase  
Aldehyde Dehydrogenase

Metabolic Activation

Free Radicals




### Phase 2

Conjugation with a small hydrophilic endogenous substance. Often to a functional group provided by a Phase I reaction, significantly increasing hydrophilicity.


UDP glucuronosyl transferases  
Glutathione-S-transferases  
Sulfotransferases  
N-acetyltransferase  
Methyltransferases

**Excretion**  
Urine & Bile

Contribution of P450 Isoforms to Human Drug Metabolism



Based on data from S.A. Wrighton.



Relative concentrations of predominant CYP isoforms expressed in human liver.

Diagnostic substrates and inhibitors of human CYP isoforms

Form	Substrate	Inhibitor
CYP1A1	7-Ethoxyresorufin	7,8 Benzoflavonea
CYP1A2	Phenacetin Caffeine	Furafylline, fluvoxamine
CYP2A6	Coumarin	Diethyldithiocarbamate, 9-methoxpsoralen
CYP2B6	6-Aminochrysene Cyclophosphamide	Not known
CYP2C8	Taxol	Quercetin
CYP2C9	Tolbutamide	Sulfaphenazole
CYP2C19	S-Mephenytoin	Tenoposide?
CYP2D6	Debrisoquine Dextromethorphan	Quindine
CYP2E1	Chlorzoxazoneb	Diethyldithiocarbamatec
CYP3A4	Testosterone Nifedipine	Troleandomycin Gestodene

Adapted from Pelkonen and Raunio, Env Health Perspectives supp 4. 105:767-774 (1997)



OXFORD BIOMEDICAL RESEARCH, INC.

FOR CONSISTENTLY RELIABLE RESULTS

[www.oxfordbiomed.com](http://www.oxfordbiomed.com)